• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
    Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
    Date:2023-06-28

    American Diabetes Association's 83rd Scientific Sessions recently concluded at the San Diego Conference Center in San Diego, California, USA, held from June 23-26, 2023. As one of the largest diabetes conferences globally, the conference drew over 12,000 esteemed physicians, scientists, and healthcare professionals from various parts of the world. This significant event showcased cutting-edge scientific breakthroughs in the diabetes field, encompassing more than 90 scientific sessions and featuring over 2,000 original research presentations1.


    Throughout the exhibition, Gan & Lee Pharmaceuticals' booth attracted experts, scholars, media representatives, doctors, and individuals associated with the diabetes field from various countries. This engagement helped enhance industry insiders' comprehension of Gan & Lee's current standing. One attendee expressed his delight, stating, "I am pleased to witness Gan & Lee's enduring dedication and profound commitment to the diabetes field. It is gratifying to see a Chinese company taking the stage at ADA to represent the voice of China.”


    In the medical information area, Gan & Lee's team prominently showcased the company's drug pipeline for the international market. The team also provided insights into the published clinical data that supports the company's Biologics License Application (BLA) at US FDA, thus laying a favorable and efficient groundwork for the subsequent launch of relevant products in the United States.


    Gan & Lee's insulin and device products have been launched in nearly 20 countries spanning four continents. Notably, this year, the company has received BLA acceptance from the U.S. FDA on its three core products – Insulin Glargine, Lispro, and Aspart. The three BLAs have entered the substantive review stage, and Gan & Lee will do their best to facilitate the approval in the U.S. and Europe. By actively expanding the product reach into diverse global markets, Gan & Lee strongly believes in fostering strong connections with the global diabetes community and extending the benefits of their products to a greater number of patients worldwide.


    References:

    1.American Diabetes Association. (2023, June 19). The American Diabetes Association commences its 83rd scientific sessions to showcase game changing diabetes advances. The American Diabetes Association Commences its 83rd Scientific Sessions to Showcase Game Changing Diabetes Advances | ADA. https://diabetes.org/newsroom/press-releases/2023/american-diabetes-association-commences-83rd-scientific-sessions-showcase-diabetes-advances


    About Gan & Lee

    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 




    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 香蕉在线精品视频在线观看6| 亚洲欧美在线观看视频| 四虎影视免费在线| 亚洲精品人成无码中文毛片| 中文字幕日韩人妻不卡一区| 蜜臀91精品国产高清在线观看| 日本成人在线网址| 国产三级电影网站| 中文有码在线观看| 翁房中春意浓王易婉艳| 成人网视频免费播放| 国产女人18毛片水真多1| 亚洲国产综合精品| gaytv.me| 精品无码国产一区二区三区av| 成人嘿嘿视频网站在线| 午夜影视在线免费观看| www.99热| 欧美精品一区二区三区在线 | 一区二区三区电影在线观看| 精品日韩在线视频一区二区三区| 成av免费大片黄在线观看| 又黄又爽又色的黄裸乳视频| peeasian人体| 污网站在线免费观看| 无码一区二区三区在线| 国产成人三级经典中文 | 99国内精品久久久久久久| 精品久久久久香蕉网| 在线视频免费观看a毛片| 可知子与野鸟君日文| 久久久久久久99精品免费| 精品视频一区二区三三区四区| 女人张腿让男桶免费视频观看| 公交车忘穿内裤被挺进小说白| a级一级黄色片| 欧美亚洲国产第一页草草| 国产午夜无码视频在线观看| 福利视频免费看| 日韩一区二紧身裤| 国产91po在线观看免费观看|